Kureha Kagaku Kogyo Kabushiki Kaisha

Kureha Chemical Industry Company, Limited

Nippon Electric Co., Ltd.

Oki Electric Industry Co., Ltd.

Takao Ando

Chikao Yoshikumi

Takayoshi Fujii

Kenichi Matsunaga

Masanori Ikuzawa

Fumio Hirose

Yoshio Ohmura

Minoru Ohhara

Koichi Niimura

Takao Furusho

Shigeaki Muto

Yuko Ikeda

Akihiko Kanno

Masahiko Fujii

Kouichi Niimura

Akira Kato

Toyohiko Nitta

Minoru Ohara

Isamu Motokawa

Masanobu Morishita

Kenichi Saito

Takako Kawabe

Yoshio Omura

Hidehiko Inoue

Mitsuru Kawasaki

Yoko Onishi

Akira Kobayashi

Akinori Watanabe

Toshihiko Wada

Katsuhide Tanoshima

Hiromitsu Makita

Noriyuki Toyoda

Akio Nagano

Kochi Niimura

Masaru Motojima

Akira Tohama

Mayumi Nohara

Katsuo Sakurai

An oligonucleotide containing a sequence of SEQ ID NO: 1: CAGTGAGTGG GTGGGGCTGG AACA, or SEQ ID NO: 2: TTAAGCTTTT ACCATGGTAA CCCC; a pharmaceutical composition comprising the oligonucleotide; and a method for treating or preventing a disease accompanied by an extracellular matrix deposition, are disclosed.

Oligonucleotides inhibitors of PAI-1 MRNA

A composition comprising as an active ingredient a compound consisting of an immunoglobulin F.sub.c fragment and an alkylating, antibiotic, or antimetabolic antitumor substance bound thereto, and a pharmaceutically acceptable carrier is disclosed. The Fc fragment moiety in the compound is stable in a living body, and thus the activity of the antitumor substance therein is maintained over a long period.

Immunoglobulin F.sub.c fragment bound to an alkylating, antibiotic, or

A novel imidazole derivative of the formula (I): ##STR1## wherein X.sub.1 is a chlorine or fluorine atom, or a hydroxy group or a salt thereof, and a pharmaceutical composition containing the same as the active ingredient.

Imidazole derivative, and pharmaceutical composition

A method of inhibiting aromatase, comprising administering to a mammal in need thereof a pharmaceutical composition comprising an effective aromatase inhibiting amount of a compound of the formula (I): ##STR1## wherein X.sub.1 is a chlorine or fluorine atom, or a hydroxy group, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Method of inhibiting aromatase

A novel azole derivative of the general formula (I): ##STR1## wherein R.sub.1 and R.sub.2 are, independently from each other, a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, x.sub.1 and x.sub.2 are, independently from each other, a hydrogen or halogen atom, or hydroxyl, cyano, or trifluoromethyl group, and Y is CH or a nitrogen atom, a process for the production thereof, and a pharmaceutical composition containing the same as the active ingredient.

Azole derivative and pharmaceutical composition

A phenylalanine-glycine derivative of the general formula (I): ##STR1## wherein R represents a residue of an antitumor substance, or a salt or ester thereof, a process for preparation thereof, and a pharmaceutical composition containing the same are described.

Phenylalanine-glycine derivatives, process for preparation thereof, and

Azole derivatives (including stereoisomers and pharmaceutically acceptable salts) of the formula: ##STR1## wherein R.sub.1 and R.sub.2 each are H or C.sub.1 -C.sub.4 alkyl; R.sub.3 is H, OH, CN, halogen, haloalkyl, C.sub.1 -C.sub.4 alkyl or phenyl, and if there are two or more R.sub.3 groups, such R.sub.3 groups may be the same or different; n is an integer from 0 to 5; Y is N or CH; and X is O, S or NH have antimycotic and aromatase inhibitory activities. Compositions containing the azole derivatives and a method of treating mycosis and estrogen-dependent diseases by administering effective quantities of the azole derivatives are also disclosed.

Azole derivatives, pharmaceutical compositions containing the same, and

Pharmaceutical compositions containing triazoles and method of treating

A phenylalanine-glycine compound of formula (I): ##STR1## wherein R represents a residue of an antitumor substance, or a salt or ester thereof, a process for preparation thereof, and a pharmaceutical composition containing the same are described. The novel conjugate of the phenylalanine-glycine compound and the antitumor substance exhibits superior antitumor activity in comparison with the case wherein an antitumor substance is administered alone or as a mixture with phenylalanine.

Phenylalanine-glycine compounds having anti-tumor activity, process for

Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R donotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, glucose, galactose and mannose, or a pharmaceutically acceptable salt thereof.

Pharmaceutical compositions containing a derivative of para-aminobenzoic

Pharmaceutical composition containing a derivative of para-aminobenzoic

Disclosed is a pharmaceutical composition containing p-aminobenzoic acid-N-D-xyloside or a pharmaceutically a acceptable salt thereof as an active ingredient.

Pharmaceutical composition containing para-amino-benzoic

Growing community of inventors

Tokyo, Japan

Takao Ando